Financial Performance - For the year ended December 31, 2022, the revenue was approximately RMB 11,912.1 million, an increase of 20.2% compared to RMB 9,914.3 million in 2021[2]. - The net profit for the year was approximately RMB 2,087.5 million, a growth of 2.8% from RMB 2,030.5 million in 2021[2]. - The contribution from the hospital group business was approximately RMB 378.3 million, representing a significant increase of 48.0% compared to the previous year[2]. - The total comprehensive income for the year was RMB 1,642.4 million, down from RMB 1,966.3 million in 2021[5]. - The basic earnings per share for ordinary shareholders was RMB 1.00, compared to RMB 0.99 in 2021[3]. - The total operating profit before tax was RMB 2,755,925 thousand in 2022, compared to RMB 2,117,810 thousand in 2021, reflecting an increase of approximately 30.0%[46]. - The total gross profit for the company was RMB 4,485.9 million, reflecting a growth of 6.8% year-on-year[180]. Assets and Liabilities - As of December 31, 2022, total assets amounted to approximately RMB 76,870.8 million, reflecting a growth of 10.0% from RMB 69,899.8 million in 2021[2]. - The total liabilities as of December 31, 2022, were RMB 46,911,383 thousand, compared to RMB 44,172,571 thousand in 2021, indicating an increase of about 6%[116]. - The company's total liabilities rose to RMB 57,167.8 million, an increase of 9.1% from RMB 52,276.5 million in 2021[155]. - Non-current assets totaled approximately RMB 48,779.8 million, an increase from RMB 44,907.2 million in 2021[6]. - The equity attributable to ordinary shareholders was approximately RMB 13,970.1 million, up 6.6% from RMB 13,104.0 million as of December 31, 2021[2]. Cash Flow and Investments - The company reported a net cash flow from operating activities of RMB 2,057,196 thousand for 2022, a substantial improvement from a net outflow of RMB 1,400,570 thousand in 2021[11]. - The company’s cash flow from operating activities was significantly impacted by an increase in trade payables by RMB 626,851 thousand in 2022[11]. - The company reported a net increase in cash and cash equivalents of 362,596 thousand RMB for 2022, compared to 326,686 thousand RMB in 2021[13]. - The company acquired subsidiaries worth RMB 1,090,280 thousand during the year, enhancing its market position[9]. - The company reported a total of RMB 668,574 thousand in other receivables, an increase from RMB 383,576 thousand in 2021[105]. Revenue Segmentation - The financial services segment generated revenue of RMB 5,706,656 thousand, while the hospital group business contributed RMB 6,205,484 thousand[36]. - The hospital group business revenue reached RMB 6,160,644 thousand in 2022, compared to RMB 4,564,357 thousand in 2021, indicating an increase of approximately 35.0%[40]. - Total customer contract revenue for the year ended December 31, 2022, was RMB 7,257,158 thousand, an increase from RMB 5,397,813 thousand in 2021, representing a growth of approximately 34.5%[40]. - The financial services segment achieved revenue of RMB 4,621 million in 2022, representing a growth of 3.4% year-on-year, while gross profit decreased by 8.8% to RMB 2,408 million[193][192]. Operational Metrics - The company added 7 new medical institutions, increasing the total number of consolidated medical institutions to 55, with a total of 13,615 beds[159]. - Total patient visits for the year were approximately 11.799 million, a growth of 37.4% compared to the previous year[166]. - Average annual revenue per bed increased to approximately RMB 470,000, a rise of about 9.6% year-on-year[165]. - The number of three and four-level surgeries reached 60,916, with their proportion rising from 62.4% in 2021 to 65.5% in 2022[167]. Employee Compensation and Expenses - The total employee benefits expense, including salaries and retirement plan contributions, rose to RMB 2,755,925 thousand in 2022 from RMB 2,117,810 thousand in 2021[46]. - The total remuneration for independent non-executive directors in 2022 was RMB 1,376,000, an increase of 100% from RMB 688,000 in 2021[50]. - Administrative expenses increased by 21.5% to RMB 899.2 million, driven by higher labor costs and the addition of newly acquired hospitals[200]. Taxation and Dividends - The total tax expense for the year was RMB 616,759,000, a decrease from RMB 661,339,000 in 2021, representing a reduction of about 6.7%[56]. - The proposed final dividend for 2022 is RMB 567,004,000, an increase from RMB 550,570,000 in 2021, which corresponds to a rise of approximately 3%[59]. Strategic Initiatives - The company plans to expand its hospital group operations through internal construction and external acquisitions or partnerships[159]. - The company aims to enhance its core capabilities and operational efficiency to achieve high-quality development and create greater value for shareholders[178]. - The company plans to invest in and establish a series of specialized kidney hospitals and dialysis centers, aiming for a rapid operational model that achieves breakeven within 6 months and profitability within 1 year[174].
环球医疗(02666) - 2022 - 年度业绩